Dr Reddy’s And Hikma Win Big On US Vascepa Patents
Hikma Considering At-Risk Launch If Originator Appeals
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
You may also be interested in...
Hikma has eyes on launching a generic of Amarin’s Vascepa in the US following FDA approval and a favorable patent ruling at the district level in March. However, with a swift appeal filed by the originator in the works, the Jordanian firm is yet to pull the trigger.
Hikma says it is prioritizing the production and delivery of medicines that are in the highest demand amid the COVID-19 pandemic, as the firm has provided a trading update that maintains its sales forecasts in the face of “challenging market conditions” and uncertainty.
Company forecasts 2020 sales as high as $700m after regulator grants broad label.